

For Public Release

NZX Limited  
Wellington

27 June 2024

### **Subsidiaries parties to Deed of Company Arrangement**

Cannasouth Limited (NZX:CBD) announces that, following the Watershed Meeting on 7 June 2024, its subsidiaries, Cannasouth Cultivation Limited, Equalis Pharmaceuticals Limited, Equalis Innovations Limited, Equalis Group New Zealand Limited and RestoreMe Clinic Limited (all subject to Deed of Company Arrangement) are parties to, and have executed, a Deed of Company Arrangement.

-ENDS-

For further information visit [www.cannasouth.co.nz](http://www.cannasouth.co.nz) or contact:

**Garry Whimp**

Administrator, Blacklock Rose Ltd  
Email: [gwhimp@blr.co.nz](mailto:gwhimp@blr.co.nz)  
Mobile: 021 587 230

**Ben Francis**

Administrator, Blacklock Rose Ltd  
Email: [bfrancis@blr.co.nz](mailto:bfrancis@blr.co.nz)  
Mobile: 021 042 6991

### **About Cannasouth Limited**

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Equalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>